|
Apr 22
|
Adicet Bio Highlights Preclinical Data Supporting IND Readiness for ADI-270 in an Oral Presentation at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting
|
|
Apr 8
|
Adicet Bio to Participate in 2024 Canaccord Genuity Horizons in Oncology Virtual Conference
|
|
Mar 21
|
Are Investors Undervaluing Adicet Bio, Inc. (NASDAQ:ACET) By 41%?
|
|
Mar 19
|
Adicet Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Company Progress
|
|
Mar 11
|
Adicet Bio to Participate in a Fireside Chat at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
|
|
Jan 25
|
Adicet Bio, Inc. Announces Closing of $98 Million Public Follow-On Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares
|
|
Jan 23
|
Adicet Bio, Inc. Announces Pricing of Public Offering
|
|
Jan 22
|
Adicet Bio, Inc. Announces Proposed Public Offering
|
|
Dec 10
|
Adicet Bio Highlights ADI-001 Expansion, Persistence and Pharmacodynamic Profile from Ongoing Phase 1 Study at the 65th American Society of Hematology (ASH) Annual Meeting
|
|
Nov 8
|
Adicet Reports Third Quarter 2023 Financial Results and Provides Business Updates
|
|
Nov 7
|
Adicet Bio to Present at the 2023 Jefferies London Healthcare Conference
|
|
Nov 2
|
Adicet Bio Announces Poster Presentation Highlighting ADI-001 Data at the 65th American Society of Hematology (ASH) Annual Meeting
|
|
Oct 31
|
Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
|
|
Aug 31
|
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
|